In an interview to CNBC-TV18's Ekta Batra and Vikas Dandekar, the Executive Chairman of Torrent Pharma, Samir Mehta spoke about the rationale behind the deal and where it would take the company in the Indian pharmaceutical market.
The Torrent Pharmaceuticals and Unichem Laboratories deal is close to fruition. On a day this Rs 3600 crore deal has been sealed, it is a good time to look at M&A activity in 2017 so far. In an interview to CNBC-TV18, Raja Lahiri of Grant Thornton, Randhir Kochhar of Ernst & Young, Vivek Gupta of KPMG and Ashvin Parekh of Ashvin Parekh Advisory Services discussed about the same.
Torrent will fund the acquisition through a mix of internal accruals and bank borrowings.
Prakash Mody, CMD, Unichem Laboratories expects the second quarter numbers to be good and the company to post double-digit growth in the next couple of quarters.
Unichem Labs logged a 12.4 percent growth in secondary sales-- made by distributors to chemists-during the December quarter when the industry grew at 5 percent, said Rakesh Parikh, VP Finance.
The drug firm reported a 3.22 percent increase in net profit to Rs. 36.2 crore for the quarter ended September 30 as sales rose.
In an interview to CNBC-TV18, Rakesh Parikh, VP-Finance & CFO, Unichem Labs spoke about the company‘s business performance in Q1 of FY14.
Rakesh Parikh, VP Finance & CFO of Unichem Laboratories said exports are driving its revenue growth. Going forward, he hopes to maintain the export margins for the rest of the financial year.
Rakesh Parikh, VP-finance of Unichem Laboratories, in an interview on CNBC-TV18 talks about his pharma company receiving approval from the US FDA for a new drug.
In an exclusive interview with CNBC-TV18, Rakesh Parikh CFO of Unichem Laboratories says the company’s Q4 outlook is on the lines of the Q3 growth and the investments made are likely to reap benefits soon. “The India formulation business is continuing in the same as in Q3. We will wrap up the year with double digit growth.”